Decreased appetite with Exelon
Decreased appetite has been added to the list of undesirable effects in the summary of product characteristics (SPC) for Exelon (rivastigmine; Novartis). Additionally, the SPC now states that, on account of increased exposure in mild to moderate hepatic impairment as observed with the oral formulation, dosing recommendations to titrate according to individual tolerability should be closely followed. Patients with clinically significant hepatic impairment may experience more dose-dependent adverse reactions. Patients with severe hepatic impairment have not been studied and so particular caution should be exercised in titrating these patients.
Citation: Electronicjuice DOI: 10.1211/PJ.2015.20068522
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Electronicjuice, and is a leading provider of authoritative pharmaceutical information used throughout the world.